Biologic Agents Continue to Outpace Overall Pharma Spending Growth
How Do US Payers View Biosimilars From a Cost Perspective?
US payers do not expect the biosimilars market to be like the generics market.
What Were the Top Five Legal Issues in Biosimilars in 2016?
Branded Trastuzumab HERITAGE Study Published in JAMA
The BPCIA Patent Dance – What Biosimilar Companies Need To Know
Live webcast on what biosimilar companies need to know.
Mundipharma Establishes Disti License from Celltrion
BioCND to Develop Lucentis Biosimilar
What Are the Eight Barriers to Biosimilar Development?
Quality, safety, and knowledge are critical.
Six Months Makes a Difference: Physicians' Attitudes About Biosimilars
A notably larger percentage of US physicians say they intend to prescribe biosimilars in the coming three years.
Top 5 Biosimilar Facts for Pharmacists
What do pharmacists need to know?
Looking to 2017: Market Access for Biosimilars
Convincing data to support the safety and effectiveness is key.
Biosimilars in Development for Chinese Market Via Sanofi Partnership
Celltrion's Biosimilar Granted Marketing Approval Recommendation
A biosimilar to Roche’s Rituxan, Truxima (rituximab) is indicated for blood cancer.
CRISPR Biotechs Create IP Pact: More Legal Battles Ahead?
Key patents for gene-editing technology are at stake.
EMA Plans Pilot for Biosimilars Developers
Breadth and depth of established data will determine study approach.
What's Next for the Europe Biosimilars Market?
New report: biosimilars outlook for 2020.
Biologics News from NASDAQ
Annual changes to the NASDAQ Biotechnology Index
What's the Fate of the BPCIA?
A new president may mean new rules.
Drug Couponing: Better or Worse for Biosimilars?
Payers will have to carefully mull limited options.
Indication-Specific Pricing and Biosimilars
Value-based health care has forced several systemic changes.
Mylan Files Application for First Herceptin® Biosimilar
Two Reminders in Biosimilar Discussions
Sometimes the actual study results are less the point than the objectives of the investigators.
Switching and Discontinuations for Remicade and Its Biosimilar in Turkey
Enthusiasm dulled for new US biosimilar Inflectra for Rheumatoid Arthritis.
Can Physician Prescribing of Biosimilars Be Influenced by Price?
New study in a small sample of physicians implies cost factor could be a big influence.
Value-Based Contracting: What's the Industry Risk-Benefit?
Gaining rapid uptake for biosimilar products is a challenge for manufacturers and payers.
Ritumixab Biosimilar Demonstrates Positive Results in Rheumatoid Arthritis
Pharmacokinetics of CT-P10 were highly similar to originator products.
Breaking News: Supreme Court Declines to Hear 'Patent Dance' Case
July federal appeals court ruling will not be heard.
Breaking News: US Asks Supreme Court to Rule on Biosimilar Patent Dance
Supreme Court will rule on the validity of the timing.
The Foundation for Building a Clinician's Confidence Over a Biosimilar Drug
Physicians will make their own decisions as to which patients might benefit most from biosimilars therapy.
Novartis: New Study on Pegfilgrastim Biosimilar Requested by FDA
Sandoz received a complete response letter from the US Food and Drug Administration (FDA) in regard to its pegfilgrastim biosimilar application, filed in 2015.
